STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG) today announces that management will participate in the upcoming investor events set out below.
-
H. C. Wainwright Annual Global Investment Conference (Rodman &
Renshaw):
September 5 & 6, 2018 – New York, USA - Séminaire Biotech Portzamparc: September 5, 2018 – Paris, France
- Large & Midcap Event: October 8 & 9, 2018 – Paris, France
- Actionaria: November 22 & 23, 2018 – Paris, France
- Bryan Garnier, Annual Healthcare Conference: November 23, 2018 – Paris, France
- Eigenkapital Forum: November 26 & 27, 2018 – Frankfurt, Germany
- Geneva MidCap Event: December 4 & 5, 2018 – Geneva, Switzerland
Next scheduled financial communication
First Half 2018 Financial Results
September 19, 2018, after close
of market
About Transgene
Transgene (Euronext: TNG), part of
Institut Mérieux, is a publicly traded French biotechnology company
focused on designing and developing targeted immunotherapies for the
treatment of cancer and infectious diseases. Transgene’s programs
utilize viral vector technology with the goal of indirectly or directly
killing infected or cancerous cells. The Company’s lead clinical-stage
programs are: TG4010, a therapeutic vaccine against non-small cell lung
cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a
therapeutic vaccine against HPV-positive head and neck cancers. The
Company has several other programs in clinical development, including
TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B)
and TG6002 (an oncolytic virus for the treatment of solid tumors).
With
its proprietary Invir.IOTM, Transgene builds on its expertise
in viral vectors engineering to design a new generation of
multifunctional oncolytic viruses.
Additional information about
Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA
